The use of mTOR inhibitors is associated with improved survival in lung transplant recipients
Y. Lebel-Shostak (Petah-Tikva, Israel), B. Pertzov (Petah-Tikva, Israel), O. Grossberger (Petah-Tikva, Israel), D. Rosengarten (Petah-Tikva, Israel), D. Shitenberg (Petah-Tikva, Israel), M. Heshing (Petah-Tikva, Israel), S. Amor (Petah-Tikva, Israel), M. Kramer (Petah-Tikva, Israel)
Source: Virtual Congress 2020 – Treatments and biomarkers for lung allograft function and outcome
Disease area: Respiratory infections
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Lebel-Shostak (Petah-Tikva, Israel), B. Pertzov (Petah-Tikva, Israel), O. Grossberger (Petah-Tikva, Israel), D. Rosengarten (Petah-Tikva, Israel), D. Shitenberg (Petah-Tikva, Israel), M. Heshing (Petah-Tikva, Israel), S. Amor (Petah-Tikva, Israel), M. Kramer (Petah-Tikva, Israel). The use of mTOR inhibitors is associated with improved survival in lung transplant recipients. 4724
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: